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Thoughvanadiumcomplexesmimictheactionofinsulin,
owing to their toxicity, research is still in progress for a new
vanadium complex with maximum efﬁcacy at low concen-
tration and without any side effects. A novel macrocyclic
binuclear oxovanadium complex was synthesized, its com-
position and structure were conﬁrmed by spectral studies
and its efﬁcacy was studied in streptozotocin-induced dia-
betic rats over a period of 30 days. The oral administra-
tion of the complex normalizes the blood glucose level in
the diabetic rats and also maintains normoglycemia after
a glucose load. The biochemical studies revealed that the
complex is not toxic to the system. The nontoxic nature of
this complex may be due to the presence of the vanadyl
ions in an intact form. The study highlights the nontoxic
and hypoglycemic effects of the new macrocyclic binuclear
oxovanadium complex.
Keywords Macrocyclic Complex; Streptozotocin Diabetes;
Vanadium
Vanadium has been recognized as an essential nutritional
requirement in higher animals. It seems to be a trace element
required for normal growth and development and also neces-
sary for the growth and survival of mammalian cell culture [1].
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Srivastava [2], Brichard and Henquin [3], Poucheret and col-
leagues [4], Schechter and Karlion [5], and Shafrir and col-
leagues [6] have extensively reviewed the antidiabetic effects
of vanadium salts, showing that administration of vanadium
salts improves glucose tolerance, lowers blood glucose levels,
and corrects the metabolic deﬁciencies in several species of di-
abetic animals and human patients. Thus, vanadate ions were
shown to mimic all or most of the actions of insulin in intact
cell systems, via a postreceptor mechanism [7–9].
Heyliger and colleagues [10] observed that vanadate nor-
malized the elevated blood glucose and depressed cardiac per-
formance of diabetic rats. Administration of vanadyl sulphate
to streptozotocin-diabetic rats resulted in a persistent normo-
glycemia [11]. Vanadyl (IV) complexes, such as vanadyl cys-
teine methyl ester, vanadyl maloante, vanadyl tartarate, and
vanadyl salicylaldehyde, normalized diabetic state in alloxan-
diabeticratssimilarlytovanadate[12].McNeillandcolleagues
[13]reportedthatadministrationofbis-maltolatooxovanadium
(IV) complex (5.8 mM) to streptozotocin (STZ)-diabetic rats
normalized blood glucose, lipid, and food and ﬂuid intake
without increasing the insulin level. Further, other complexes
such as bis-glycinato oxovanadium (IV) complex [14] and bis-
(pyrrolidin-N-carbodithiato)vanadium(IV)complex[15]were
also found to be effective in STZ-diabetic rats.
Though vanadium possesses a range of diabetes-corrective
actions, its toxicity is of more concern in rodents and humans
[16]. In most studies of the insulin-like effects of vanadium in
diabetic rats and mice, oral administration of vanadium was
considered to be toxic and the toxicity increased with increas-
ing concentration of vanadium [17, 18]. The use of various
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chelating agents and ligands to reduce vanadium toxicity and
improve insulin potency are the major recent goals of vana-
dium research. In this aspect, vanadium complex with macro-
cyclic ligand to reduce its toxicity was formulated and its hy-
poglycemic efﬁcacy was determined in the present study.
MATERIALS AND METHODS
Synthesis of Macrocyclic Binuclear
Oxovanadium (IV) Complex [19]
Synthesis of Precursor Compound: 6,6 -piperazine-1,4
diylmethylene-bis (4-methyl-2-formyl phenol)
A mixture of piperazine, paraformaldehyde and 4-methyl-
2-formyl phenol (1:2:2) in ethanol acetic acid medium was
stirred for 6 hours at 60◦C. The reaction mixture was cooled
to room temperature and neutralized with solid sodium car-
bonate. Ethanol was removed by distillation under reduced
pressure and the residue was extracted with chloroform. Re-
moval of chloroform by distillation yielded a pale yellow crys-
talline solid, which was further puriﬁed by silica gel column
chromatography.
Synthesis of Macrocyclic Binuclear Oxovanadium (IV)
Complex
The precursor compound was dissolved in 20 mL of chloro-
form.Tothissolution,oneequivalentofoxovanadium(IV)sul-
phate, dissolved in 50 mL methanol, was added. The resulting
yellow reaction mixture was reﬂuxed for about 30 minutes. To
theaboveresultingyellow-coloredsolution,1equivalentofox-
ovanadium(IV)acetylacetonateand1equivalentofethylenedi-
aminewereaddedandreﬂuxedfor1hour.Onslowevaporation
of the solvent at room temperature, a dark brown–colored com-
pound was obtained, which was washed with ether and dried
in a vacuum dessicator. The complex was recrystallized from
methanol. The complex was characterized by elemental anal-
ysis, and ultraviolet (UV)-visible, infrared (IR), and electron
spin resonance (ESR) spectroscopies (Figure 1). The complex
was administered to rats as an aqueous suspension.
Animals
Male albino rats of the Wistar strain, weighing around 160
to 180 g, were purchased from Tamil Nadu Veterinary and An-
imal Sciences University, Chennai, for the present study. They
were acclimatized to animal house conditions, fed with com-
mercial pelleted rat chow (Hindustan Lever Ltd., Bangalore),
and had free access to water. The experiments were designed
and conducted in accordance with the ethical norms approved
by Ministry of Social Justices and Empowerment, Government
ofIndia,andInstitutionalAnimalEthicsCommitteeguidelines.
FIGURE 1
Synthesis of macrocyclic binuclear oxovanadium complex.
Experimental Protocol
Animals were fasted for 24 hours before inducing diabetes
with STZ. Animals were anesthetized with ether and were in-
traperitoneally administered with freshly prepared solution of
streptozotocin (55 mg/kg body weight) in 0.1 M citrate buffer
(pH 4.5) [20]. After 48 hours, rats with blood glucose levels
above 250 mg/dL were considered as diabetic rats and were
used for the present study. Control animals received citrate
buffer alone. The normal and overt diabetic rats were grouped
as follows:
Group I: Control rats administered with saline
Group II: Vanadium complex administered control rats
(Aqueoussuspensionof5mg/kgbodyweight/mL/dayorally
for 30 days)
Group III: STZ-diabetic rats
Group IV: STZ-diabetic rats treated with vanadium complex
(Aqueoussuspensionof5mg/kgbodyweight/mL/dayorally
for 30 days)
After 30 days of treatment, the rats were euthanized and
blood was collected using EDTA as anticoagulant. The whole
blood was used for the estimation of glucose [21], urea [22],
hemoglobin [23], and glycated hemoglobin [24]. The plasma
was used for the assay of cholesterol [25], creatinine [26], pro-
teins [27], glutamate oxaloacetate transaminase (GOT), and
glutamate pyruvate transaminase (GPT) [28].
Glucose Tolerance Test
After 4 weeks of treatment (on the 29th day), fasting blood
sample was taken from all the groups of rats. Four more blood
samples were collected at 30-, 60-, 90-, and 120-minute inter-
vals [29] after administration of glucose at a concentration of
2 g/kg body weight [30]. All the blood samples were collectedHYPOGLYCEMIC EFFECT OF MACROCYCLIC VANADIUM COMPLEX 139
TABLE 1
Effect of vanadium complex on blood sugar level in glucose-loaded normal and experimental groups of rats
Blood sugar level (mg/dL)
Group Fasting 30 min 60 min 90 min 120 min
Normal control 81 ± 5.7 147 ± 8.3 169 ± 9.2 121 ± 8.9 85 ± 6.1
Vanadium control 79 ± 5.3 149 ± 8.5 165 ± 9.1 116 ± 7.8 81 ± 5.8
Diabetic control 254 ± 11.9∗ 319 ± 18.9∗ 391 ± 19.5∗ 350 ± 17∗ 315 ± 18∗
Diabetic, vanadium-treated 93 ± 6.8∗ 152 ± 9.1∗ 177 ± 10.1∗ 125 ± 9.8∗ 98 ± 8.9∗
Note. Values are given as mean ± SD for groups of 6 animals in each group.
Values are statistically signiﬁcant at ∗P <. 05. Vanadium-treated control rats were compared with control rats. Diabetic
control rats were compared with control rats. Vanadium-treated diabetic rats were compared with diabetic control.
with potassium oxalate and sodium ﬂuoride solution for the
estimation of glucose.
Statistical Analysis
All the grouped data were statistically evaluated with
SPSS/7.5software.Hypothesistestingmethodsincluded1-way
analysisofvariance(ANOVA)followedbyleastsigniﬁcantdif-
ference(LSD)test. P valuesoflessthan.05wereconsideredto
indicate statistical signiﬁcance. All the results were expressed
as mean ± SD for 6 animals in each group.
RESULTS
Changes in body weight gain at regular intervals during the
experimental period are shown in Figure 2. The body weight
wasfoundtobeincreasedinbothnormalcontrols(groupI)and
FIGURE 2
Change in body weight gain of normal and experimental
groups of rats.
vanadium-treatedcontrolgroupofrats(groupII).Thereduction
in body weight in STZ-diabetic rats (group III) were restored
to near normal in diabetic rats treated with vanadium complex
(group IV).
Table 1 shows the blood glucose levels of normal and ex-
perimental groups of rats after oral administration of glucose.
In vanadium complex–treated control rats, the change in blood
glucoselevelswasinparwiththatofthenormalrats.Indiabetic
control rats, the peak increase in blood glucose concentration
was observed after 1 hour and it remained high over the next
hour. Vanadium complex–treated diabetic rats showed signif-
icant decrease in blood glucose concentration at 1 hour and
2 hours when compared with diabetic control rats. The glucose
tolerance effect was more pronounced after a 2-hour interval.
Table 2 shows the levels of blood glucose, plasma choles-
terol, total proteins, and urine sugar in all the groups of rats.
The increase in the levels of glucose and cholesterol and a con-
comitant decrease in the levels of plasma proteins in diabetic
rats were restored to near normal levels in vanadium complex–
treated diabetic rats. Urine glucose present in diabetic rats was
absent in vanadium complex–treated diabetic rats. No signif-
icant alterations were observed in vanadium complex–treated
control rats.
Figure 3 shows the levels of hemoglobin and glycated
hemoglobin in normal and experimental groups of rats. The
increaseinthelevelsofglycatedhemoglobinandacorrespond-
ing decrease in the levels of hemoglobin found in diabetic rats
were restored to near normal in vanadium complex–treated di-
abetic rats. No signiﬁcant alterations were observed in normal
rats treated with vanadium complex.
Table 3 depicts the blood urea and plasma creatinine lev-
els and activities of GOT and GPT in normal and experimen-
tal groups of rats. The increased levels of urea and creatinine
and increase in the activities of these enzymes in diabetic rats
were restored to near normalcy in vanadium complex–treated
diabetic rats. No signiﬁcant changes were found in vanadium
complex–treated control rats.140 B. RAMACHANDRAN ET AL.
TABLE 2
Levels of blood glucose, plasma cholesterol, total proteins, and urine sugar in normal
and experimental groups of rats
Blood glucose Cholesterol Proteins
Group (mg/dL) (mg/dL) (g/dL) Urine sugar
Normal control 90 ± 6.1 86 ± 3.1 7.3 ± 0.3 Nil
Vanadium control 82 ± 5.9 80 ± 2.8∗ 7.1 ± 0.5 Nil
Diabetic control 257 ± 18.9∗ 192 ± 5.1∗ 5.1 ± 0.8∗ +++
Diabetic + vanadium-treated 99 ± 7.6∗ 95 ± 3.3∗ 6.8 ± 0.3∗ Nil
Note. Values are given as mean ± SD for groups of 6 animals in each group.
Values are statistically signiﬁcant at ∗P <. 05. Vanadium-treated control rats were compared with control
rats. Diabetic control rats were compared with control rats. Vanadium-treated diabetic rats were compared
with diabetic control.
+++ indicates more than 2% sugar.
DISCUSSION
The mononuclear or binuclear oxovanadium complexes so
far tested for their hypoglycemic activities contain only acyclic
ligands and hence the leaching or hydrolysis of vanadyl ions
from these complexes is much easier than in mononuclear or
binuclearcomplexeshavingmacrocyclicligands,whicharerel-
atively more stable. This has encouraged us to develop the
macrocyclic binuclear oxovanadium complexes whose hypo-
glycemic and nontoxic nature are revealed in the present study.
The enhancement of body weight in the vanadium-
administered group of rats may be correlated with the obser-
vation that vanadium administration enhances the growth up to
FIGURE 3
Levels of Hb and Gly Hb in normal and experimental groups
of rats.
40% by increasing the metabolic activity of the system when
compared to control rats [31]. This indicates that vanadium in-
creases glucose metabolism and thus enhances body weight in
STZ-diabetic rats.
Vanadyl ions were reported to exert a marked glucose tol-
erance after a glucose load in STZ-diabetic rats [32]. Vanadyl
ion, owing to its wide range of action by inducing insulin re-
ceptortyrosinekinasesandbyinhibitingphosphotyrosinephos-
phatases, enhances the basal rates of glucose uptake and pre-
sumed metabolism of glucose by liver and muscle [20]. This
results in reverting of hyperglycemic state to normoglycemic
state after a glucose load in STZ-diabetic rats. Further, the
macrocyclic vanadium complex enhances glucose metabolism
by regularizing the activity of glucose-metabolizing enzymes,
suchashexokinase,glycogenphosphorylase,andglycogensyn-
thase [33], which resulted in decrease in blood glucose levels
in vanadium complex–administered diabetic rats. This may be
the reason for marked glucose tolerance exhibited by the vana-
dium complex to glucose load and thus alleviates diabetes in
STZ-diabetic rats treated with macrocyclic vanadium complex.
Obesity is assumed to be a risk factor for insulin resistance
and hence is a major cause of non–insulin-dependent diabetes
mellitus. In addition to its inﬂuence on glucose homeostasis
and carbohydrate metabolism, vanadium also plays a major
role in lipid metabolism, restoring the altered plasma lipids and
lipoprotein proﬁle in STZ-diabetes to near normal levels [34].
Further, by regulating the key regulatory enzyme 3-hydroxy-3-
methyl glutaryl coenzyme A synthase, the plasma cholesterol
level is regulated by vanadium in STZ-diabetic rats [35]. Thus
macrocyclic vanadium complex alleviates insulin resistance by
high plasma cholesterol in diabetic rats.
In uncontrolled or poorly controlled diabetes, there is
an increased glycation of a number of proteins, includ-
ing hemoglobin and α-crystalline of lens [36]. Glycated
hemoglobin (HbA1C) was found to increase in patients withHYPOGLYCEMIC EFFECT OF MACROCYCLIC VANADIUM COMPLEX 141
TABLE 3
Levels of blood urea, plasma creatinine, and activities of plasma glutamate oxaloacetic
transaminase and glutamate pyruvic transaminases in normal and experimental groups of rats
Group Urea Creatinine GOT GPT
Normal control 18 ± 2.9 0.69 ± 0.03 17 ± 1.6 13 ± 0.9
Vanadium control 19 ± 2.5 0.61 ± 0.02∗ 18 ± 0.6 12 ± 0.8
Diabetic control 38 ± 3.1∗ 0.98 ± 0.04∗ 25 ± 1.1∗ 26 ± 1.1∗
Diabetic + vanadium-treated 20 ± 2.2∗ 0.58 ± 0.03∗ 16 ± 0.8∗ 16 ± 1.2∗
Note. Values are given as mean ± SD for groups of 6 animals each.
Values are statistically signiﬁcant at ∗P <. 05. Vanadium-treated control rats were compared with control rats. Diabetic
control rats were compared with control rats. Vanadium-treated diabetic rats were compared with diabetic control.
Activitiesareexpressedas:urea(mg/dL);creatinine(mg/dL);GOT,GPT(nmolesofpyruvateliberated/h/mgofprotein).
diabetes mellitus to approximately 16% and the amount of in-
creaseisdirectlyproportionaltothefastingbloodglucoselevel
[37]. The decreased level of total hemoglobin in diabetic rats
is mainly due to increased formation of glycated hemoglobin
[38], which is reverted back to normal levels by the admin-
istration of vanadium complex. Vanadate restores the normal
levels of glycated hemoglobin in STZ-induced diabetes by its
normoglycemic effect [39]. The macrocyclic vanadium com-
plex also controls the glycation of hemoglobin by virtue of its
normoglycemic activity.
During diabetes, there is increased protein catabolism, with
ﬂow of amino acids into the liver, which feeds gluconeogen-
esis [40]. Dighe and colleagues [41] have reported that accel-
erated proteolysis of uncontrolled diabetes occurs as a result
of deranged glucagon-mediated regulation of cAMP formation
in insulin deﬁciency. This accounts for the observed decrease
in the total protein content in STZ-induced diabetic rats. Ad-
ministration of vanadium complex to diabetic rats signiﬁcantly
inhibits proteolysis caused by insulin deﬁciency and thus in-
creases the level of plasma proteins to near normalcy.
Because early reports have claimed that vanadium is toxic
to mammals, we undertook a few experiments to elucidate this
issue.MorrisandLeon[42]reportedthatincreasedureaproduc-
tionindiabetesmightbeduetoenhancedcatabolismofliverand
plasma proteins. However, in the present study, the vanadium
complextreateddiabeticratsshowednearnormalvaluesinurea
and creatinine levels, which reﬂects the non-toxic nature of the
vanadium complex. It is a well-known fact that vanadium tends
tobestoredinthekidney,whichistheprimarystoragesiteunder
normalconditions.Further,kidneyisoneoftheimportanttarget
organs of vanadium toxicity [43, 44]. No signiﬁcant alterations
in plasma urea levels in vanadium-treated control and diabetic
rats indicate normal kidney function and thus reveal the non-
toxic nature of macrocyclic binuclear oxovanadium complex
used in the present study. Also, a rise in GPT activity is almost
alwaysduetohepatocellulardamagefollowedbycardiactissue
damage and is usually accompanied by a rise in GOT activity
[45].TheincreaseintheactivitiesofGOTandGPTisalsofound
indiabeticBBrats[46].ThereversalofGPTandGOTactivities
in vanadium complex–treated diabetic rats towards near nor-
malcy further strengthens the nontoxic nature of the complex.
Further in-depth studies on the mechanism of action of this
macrocyclic binuclear oxovanadium complex would render us
withanefﬁcientnontoxichypoglycemicdruginthenearfuture.
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